Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_373

Reference

Title : Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study - Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_373
Author(s) : Unni LK , Radcliffe J , Latham G , Sunderland T , Martinez R , Potter W , Becker RE
Ref : Methods Find Exp Clin Pharmacol , 16 :373 , 1994
Abstract :

Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Single (0.1-0.6 mg/kg) and multiple 5-day (0.1-0.3 mg/kg) doses of HP were administered to 21 young normal volunteers. The relationship between logarithmic dose (mg/kg) and peak inhibition of red blood cell (RBC) ChE was linear with dose. In one subject given 0.6 mg/kg of HP, concentration in plasma was 0.68 ng/ml at 2 h and gradually declined to below the detection limit by 4 h. Peak plasma and RBC ChE inhibitions of 31.2% and 55.8% were achieved at 2 h for both with a 0.6 mg/kg dose. Chronic studies did not result in any accumulation of ChE inhibition up to 0.2 mg/kg b.i.d., whereas at 0.3 mg/kg b.i.d. 10-15% RBC ChE inhibition was maintained. Higher levels of ChE inhibition can be achieved with HP than with its parent compound, Phy. Red blood cell ChE inhibition recovered more slowly than plasma even though the maximum inhibition was similar for both enzymes.

PubMedSearch : Unni_1994_Meth.Find.Exp.Clin.Pharmacol_16_373
PubMedID: 7934317

Related information

Citations formats

Unni LK, Radcliffe J, Latham G, Sunderland T, Martinez R, Potter W, Becker RE (1994)
Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study
Methods Find Exp Clin Pharmacol 16 :373

Unni LK, Radcliffe J, Latham G, Sunderland T, Martinez R, Potter W, Becker RE (1994)
Methods Find Exp Clin Pharmacol 16 :373